Uniphar plc (AIM: UPR)
London
· Delayed Price · Currency is GBP · Price in GBX 173.60
+0.60 (0.35%)
Jan 22, 2025, 8:37 AM GMT+1
Uniphar Revenue
Uniphar had revenue of 1.37B EUR in the half year ending June 30, 2024, with 37.88% growth. This brings the company's revenue in the last twelve months to 2.68B, up 15.64% year-over-year. In the year 2023, Uniphar had annual revenue of 2.55B with 23.30% growth.
Revenue (ttm)
2.68B EUR
Revenue Growth
+15.64%
P/S Ratio
n/a
Revenue / Employee
893.69K EUR
Employees
3,000
Market Cap
470.32M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.55B | 482.39M | 23.30% |
| Dec 31, 2022 | 2.07B | 127.52M | 6.56% |
| Dec 31, 2021 | 1.94B | 119.30M | 6.54% |
| Dec 31, 2020 | 1.82B | 158.57M | 9.52% |
| Dec 31, 2019 | 1.67B | 247.39M | 17.45% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 38.20B |
| GSK plc | 31.31B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| ConvaTec Group | 1.74B |
| Hikma Pharmaceuticals | 2.39B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |
Uniphar News
- 5 months ago - Uniphar reports increase in profits and revenues in first half of 2024 - Independent Ireland